{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:44:45Z","timestamp":1649169885257},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,15]]},"DOI":"10.2169\/internalmedicine.2806-19","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T22:02:49Z","timestamp":1563746569000},"page":"3243-3246","source":"Crossref","is-referenced-by-count":1,"title":["Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine"],"prefix":"10.2169","volume":"58","author":[{"given":"Misato","family":"Ogata","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"},{"name":"Cancer Treatment Center, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukimasa","family":"Hatachi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Hyogo College of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.","DOI":"10.1056\/NEJMoa020461"},{"key":"2","unstructured":"2. Network NCC. Soft Tissue Sarcoma Ver2. 2018 [Internet]. [cited 2018 Dec 31]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf"},{"key":"3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419, 2008.","DOI":"10.1016\/j.humpath.2008.06.025"},{"key":"5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"5. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272, 2012.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","volume":"369","author":"BP Rubin","year":"2007","unstructured":"6. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 369: 1731-1741, 2007.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"7","unstructured":"7. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360-5367, 2008."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35, 2006.","DOI":"10.1200\/JCO.2005.02.2194"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Komatsu Y, Ohki E, Ueno N, et al. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 45: 1016-1022, 2015.","DOI":"10.1093\/jjco\/hyv126"},{"key":"10","unstructured":"10. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011-1021, 2003."},{"key":"11","unstructured":"11. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66: 357-371, 2010."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61: 515-524, 2008.","DOI":"10.1007\/s00280-007-0498-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352-5359, 2008.","DOI":"10.1200\/JCO.2007.15.7461"},{"key":"14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12885-016-2051-5","volume":"16","author":"P Reichardt","year":"2016","unstructured":"14. Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 16: 22, 2016.","journal-title":"BMC Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_2806-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T03:44:02Z","timestamp":1573875842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_2806-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":14,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2806-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}